Greek BRCA1 and BRCA2 mutation spectrum: Two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients

Breast Cancer Research and Treatment

Volumn 107, Issue 3, 2008, Pages 431-441

  Konstantopoulou, Irene ^a,b   Rampias, Theodore ^b   Ladopoulou, Angela ^a,b   Koutsodontis, George ^b   Armaou, Sophia ^a   Anagnostopoulos, Theodore ^a   Nikolopoulos, George ^a   Kamakari, Smaragda ^b   Nounesis, George ^a   Stylianakis, Antonis ^c   Karanikiotis, Charisios ^d   Razis, Evangelia ^e   Gogas, Helen ^f   Keramopoulos, Antonios ^g   Gaki, Vassiliki ^g   Markopoulos, Christos ^h   Skarlos, Dimosthenis ⁱ   Pandis, Nikos ^a,j   Bei, Thalia ^b   Arzimanoglou, Iordanis ^a,k   Fountzilas, George ^a,l,m   Yannoukakos, Drakoulis ^a   more..

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b Biogenomica   (Greece)

^c KAT HOSPITAL   (Greece)

^d General Army Hospital   (Greece)

^e HYGEIA HOSPITAL   (Greece)

^f UNIVERSITY OF ATHENS   (Greece)

^g IASO   (Greece)

^h Hellenic Society of Breast Surgeons   (Greece)

ⁱ Henri Dunant Hospital   (Greece)

^j SAINT SAVVAS HOSPITAL   (Greece)

^k AARHUS UNIVERSITY   (Denmark)

^l ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^m Hellenic Cooperative Oncology Group   (Greece)

more..

Author keywords

BRCA1; BRCA2; Breast cancer; dHPLC; Genetic testing; Germline mutation; Greece; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; BREAST CANCER; CANCER SCREENING; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GREECE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL;

BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; GENES, BRCA1; GENES, BRCA2; GREECE; HUMANS; MUTATION; OVARIAN NEOPLASMS;

EID: 38649139360     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9571-2     Document Type: Article

References (35)

1. Walsh T, King MC (2007) Ten genes for inherited breast cancer. Cancer Cell 11:103-105
2. Couch FJ (2004) Genetic epidemiology of BRCA1. Cancer Biol Ther 3:509-514
3. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689
4. Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108:171-182
5. Szabo CI, King MC (1997) Population genetics of BRCA1 and BRCA2. Am J Hum Genet 60:1013-1020
6. Neuhausen SL (1999) Ethnic differences in cancer risk resulting from genetic variation. Cancer 86:2575-2582
7. Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, Tomlinson G, Cannon-Albright L, Bishop T, Kelsell D, Solomon E, Weber B, Couch F, Struewing J, Tonin P, Durocher F, Narod S, Skolnick MH, Lenoir G, Serova O, Ponder B, Stoppa-Lyonnet D, Easton D, King MC, Goldgar DE (1996) Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet 58:271-280
8. Tonin P, Serova O, Lenoir G, Lynch H, Durocher F, Simard J, Morgan K, Narod S (1995) BRCA1 mutations in Ashkenazi Jewish women. Am J Hum Genet 57:189
9. Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjord JE (1996) A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 13:117-119
10. Moller P, Heimdal K, Apold J, Fredriksen A, Borg A, Hovig E, Hagen A, Hagen B, Pedersen JC, Maehle L (2001) Genetic epidemiology of BRCA1 mutations in Norway. Eur J Cancer 37:2428-2434
11. Konstantopoulou I, Kroupis C, Ladopoulou A, Pantazidis A, Boumba D, Lianidou ES, Petersen MB, Florentin L, Chiotellis E, Nounesis G, Efstathiou E, Skarlos D, Tsionou C, Fountzilas G, Yannoukakos D (2000) BRCA1 mutation analysis in breast/ovarian cancer families from Greece. Hum Mutat 16:272-273
12. Armakolas A, Ladopoulou A, Konstantopoulou I, Pararas B, Gomatos IP, Kataki A, Konstadoulakis MM, Stathopoulos GP, Markopoulos C, Leandros E, Gogas I, Yannoukakos D, Androulakis G (2002) BRCA2 gene mutations in Greek patients with familial breast cancer. Hum Mutat 19:81-82
13. Ladopoulou A, Kroupis C, Konstantopoulou I, Ioannidou-Mouzaka L, Schofield AC, Pantazidis A, Armaou S, Tsiagas I, Lianidou E, Efstathiou E, Tsionou C, Panopoulos C, Mihalatos M, Nasioulas G, Skarlos D, Haites NE, Fountzilas G, Pandis N, Yannoukakos D (2002) Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed. Cancer Lett 185:61-70
14. Belogianni I, Apessos A, Mihalatos M, Razi E, Labropoulos S, Petounis A, Gaki V, Keramopoulos A, Pandis N, Kyriacou K, Hadjisavvas A, Kosmidis P, Yannoukakos D, Nasioulas G (2004) Characterization of a novel large deletion and single point mutations in the BRCA1 gene in a Greek cohort of families with suspected hereditary breast cancer. BMC Cancer 4:61
15. Claes K, Poppe B, Coene I, Paepe AD, Messiaen L (2004) BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families. Br J Cancer 90:1244-1251
16. Abkevich V, Zharkikh A, Deffenbaugh AM, Frank D, Chen Y, Shattuck D, Skolnick MH, Gutin A, Tavtigian SV (2004) Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet 41:492-507
17. Judkins T, Hendrickson BC, Deffenbaugh AM, Eliason K, Leclair B, Norton MJ, Ward BE, Pruss D, Scholl T (2005) Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations. Cancer Res 65:10096-10103
18. Armaou S, Konstantopoulou I, Anagnostopoulos T, Razis E, Boukovinas I, Xenidis N, Fountzilas G, Yannoukakos D (2007) Novel genomic rearrangements in the BRCA1 gene detected in greek breast/ovarian cancer patients. Eur J Cancer 43:443-453
19. Ladopoulou A, Konstantopoulou I, Armaou S, Efstathiou E, Mihalatos M, Nasioulas G, Bardi G, Pandis N, Yannoukakos D, Athens (2002) A change in the last base of BRCA1 exon 23, 5586G → A, results in abnormal RNA splicing. Cancer Genet Cytogenet 134:175-177
20. Kroupis C, Lianidou E, Goutas N, Ladopoulou A, Konstantopoulou I, Pantazidis A, Yannoukakos D, Efstathiou E, Vourlidis N, Tsionou C (2003) Atypical medullary breast carcinoma in a family carrying the 5382insC BRCA-1 mutation. Breast J 9:260-262
21. Rafnar T, Benediktsdottir KR, Eldon BJ, Gestsson T, Saemundsson H, Olafsson K, Salvarsdottir A, Steingrimsson E, Thorlacius S (2004) BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study. Eur J Cancer 40:2788-2793
22. Borg A, Dorum A, Heimdal K, Maehle L, Hovig E, Moller P (1999) BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations. Dis Markers 15:79-84
23. Gorski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, Mackiewicz A, Stawicka M, Bebenek M, Sorokin D, Fiszer-Maliszewska L, Haus O, Janiszewska H, Niepsuj S, Gozdz S, Zaremba L, Posmyk M, Pluzanska M, Kilar E, Czudowska D, Wasko B, Miturski R, Kowalczyk JR, Urbanski K, Szwiec M, Koc J, Debniak B, Rozmiarek A, Debniak T, Cybulski C, Kowalska E, Toloczko-Grabarek A, Zajaczek S, Menkiszak J, Medrek K, Masojc B, Mierzejewski M, Narod SA, Lubinski J (2004) A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 110:683-686
24. Jobling MA, Tyler-Smith C (2003) The human Y chromosome: an evolutionary marker comes of age. Nat Rev Genet 4:598-612
25. Backe J, Hofferbert S, Skawran B, Dork T, Stuhrmann M, Karstens JH, Untch M, Meindl A, Burgemeister R, Chang-Claude J, Weber BH (1999) Frequency of BRCA1 mutation 5382insC in German breast cancer patients. Gynecol Oncol 72:402-406
26. Hamel N, Foretova L, Narod SA, Tihomirova L, Zajac V, Ciernikova S, Armaou S, Yannoukakos D, Greenwood C, Foulkes WD (2006) Investigating the origins of the BRCA1 mutation c.5385dupC. In: Abstracts of the 56th Annual Meeting of the American Society of Human Genetics, New Orleans, Louisiana, USA, October 10-13 2006, p 203
27. Chenevix-Trench G, Healey S, Lakhani S, Waring P, Cummings M, Brinkworth R, Deffenbaugh AM, Burbidge LA, Pruss D, Judkins T, Scholl T, Bekessy A, Marsh A, Lovelock P, Wong M, Tesoriero A, Renard H, Southey M, Hopper JL, Yannoukakos K, Brown M, Easton D, Tavtigian SV, Goldgar D, Spurdle AB (2006) Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 66:2019-2027
28. Glover JN (2006) Insights into the molecular basis of human hereditary breast cancer from studies of the BRCA1 BRCT domain. Fam Cancer 5:89-93
29. Mirkovic N, Marti-Renom MA, Weber BL, Sali A, Monteiro AN (2004) Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition. Cancer Res 64:3790-3797
30. Williams RS, Chasman DI, Hau DD, Hui B, Lau AY, Glover JN (2003) Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations. J Biol Chem 278:53007-53016
31. Joo WS, Jeffrey PD, Cantor SB, Finnin MS, Livingston DM, Pavletich NP (2002) Structure of the 53BP1 BRCT region bound to p53 and its comparison to the BRCA1 BRCT structure. Genes Dev 16:583-593
32. Hayes F, Cayanan C, Barilla D, Monteiro AN (2000) Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation. Cancer Res 60:2411-2418
33. Carvalho MA, Marsillac SM, Karchin R, Manoukian S, Grist S, Swaby RF, Urmenyi TP, Rondinelli E, Silva R, Gayol L, Baumbach L, Sutphen R, Pickard-Brzosowicz JL, Nathanson KL, Sali A, Goldgar D, Couch FJ, Radice P, Monteiro AN (2007) Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res 67:1494-1501
34. Karchin R, Monteiro AN, Tavtigian SV, Carvalho MA, Sali A (2007) Functional impact of missense variants in BRCA1 predicted by supervised learning. PLoS Comput Biol 3:e26
35. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA (2006) Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98:1694-1706